MBX Biosciences Canvuparatide Shows Promise in Hypoparathyroidism Treatment

Background

Hypoparathyroidism is a rare endocrine disorder characterized by a deficiency in parathyroid hormone (PTH), leading to decreased calcium levels in the blood. Current treatments involve high doses of oral calcium and active vitamin D supplements, which do not address the underlying cause of the disease.

Study Details

The Phase 2 Avail™ trial (NCT06465108) was a randomized, double-blind, placebo-controlled study involving 64 patients. Patients were administered canvuparatide at varying doses (400ug, 600ug, 800ug) via subcutaneous injection once weekly. The primary endpoint was achieving normal albumin-adjusted serum calcium levels while reducing dependency on active vitamin D and calcium supplements.

Results

The trial met its primary endpoint, with 63% of canvuparatide-treated patients achieving the desired outcome at Week 12 (p=0.042). Furthermore, 79% of patients in the open-label extension achieved responder status at 6 months. Positive findings were also observed in bone and kidney biomarkers, suggesting enhanced bone remodeling and reduced urine calcium levels.

Competitive Landscape

Canvuparatide aims to compete with existing treatments like Yorvipath from Ascendis Pharma. The once-weekly administration and potential for continuous PTH exposure could provide a significant advantage over current daily dosing regimens.

Hypoparathyroidism is a rare endocrine disorder caused by a deficiency of parathyroid hormone (PTH), leading to decreased calcium levels in the blood.

Canvuparatide is a parathyroid hormone peptide prodrug designed as a potential long-acting hormone replacement therapy for the treatment of hypoparathyroidism.

Do you think canvuparatide will become a preferred treatment option for hypoparathyroidism? Share your thoughts in the comments below!

Share this article with others who need to stay ahead of this trend!